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ABSTRACT
Objective: To derive a simple score for estimating the long-term risk of osteoporotic and hip frac-
ture in individual patients with MS.
Methods: Using the UK General Practice Research Database linked to the National Hospital Reg-
istry (1997–2008), we identified patients with incident MS (n ! 5,494). They were matched 1:6
by year of birth, sex, and practice with patients without MS (control subjects). Cox proportional
hazards models were used to calculate the long-term risk of osteoporotic and hip fracture. We
fitted the regression model with general and specific risk factors, and the final Cox model was
converted into integer risk scores.
Results: In comparison with the FRAX calculator, our risk score contains several new risk factors
that have been linked with fracture, which include MS, use of antidepressants, use of anticonvul-
sants, history of falling, and history of fatigue. We estimated the 5- and 10-year risks of osteopo-
rotic and hip fracture in relation to the risk score. The C-statistic was moderate (0.67) for the
prediction of osteoporotic fracture and excellent (0.89) for the prediction of hip fracture.
Conclusion: This is the first clinical risk score for fracture risk estimation involving MS as a risk
factor. Neurology® 2012;79:922–928
GLOSSARY
BMD ! bone mineral density; BMI ! body mass index; GC ! glucocorticoid; GPRD ! General Practice Research Database;
MS!multiple sclerosis.
Multiple sclerosis (MS) is a chronic inflammatory disorder of the brain and spinal cord charac-
terized by damage to myelin and axons. MS is one of the most common causes of neurologic
disability in young adults.1 Previous epidemiologic studies have shown that patients with MS
are at risk of fractures, especially fractures of the hip.2,3 This risk may be caused by different
underlying mechanisms, which include low bone mineral density (BMD)4–9 and increased risk
of falling.10–12 Explanations for low BMD in MS include immobility,6,7 vitamin D defi-
ciency,6,9 and use of glucocorticoids (GCs).4,7 The increased risk of falling may be explained by
poorer postural balance, impaired vision, disability, or spasticity.10,12 We have shown that
absolute risks of fracture were substantial when patients with MS were older than 60 years.2 It is
currently possible to estimate an individual’s risk of fracture with FRAX13 or the Garvan
calculator.14
The FRAX tool has been developed by the World Health Organization to evaluate fracture
risk of patients.13 FRAX uses easily obtainable clinical risk factors, with or without femoral
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neck BMD, to estimate a 10-year probability
of hip fracture and osteoporotic fracture. The
FRAXmodel uses data derived from 9 cohorts
from around the world, including centers
from North America, Europe, Asia, and
Australia and has been validated in 11 inde-
pendent cohorts with a similar geographic
distribution.15 For fracture prediction with-
out BMD, the C-statistic for hip fracture was
0.66 in the validation cohorts, and for osteo-
porotic fracture, it was 0.60. FRAX models
have been calibrated to the epidemiology of
many countries, including the United King-
dom, and are available through the Web.16
Risk factors that are incorporated in FRAX
include age, sex, body mass index (BMI), his-
tory of fracture, parental history of fracture,
smoking, use of GCs, history of rheumatoid
arthritis, secondary osteoporosis, and high al-
cohol consumption. Many clinicians have a
wish list of risk factors not considered in
FRAX, including many other risk factors for
secondary osteoporosis and the inclusion of
risk of falls.17
MS is one of the risk factors for fracture
that is not incorporated in FRAX. To our
knowledge, there is currently no clinical risk
score available for the calculation of the long-
term risk of fracture in patients with MS.
Such a score might be a useful tool to identify
those patients with MS who would be candi-
dates for BMD screening or pharmacologic
interventions. In patients with low BMD, the
use of bisphosphonates, strontium ranelate, or
raloxifene has been approved for the preven-
tion of fractures.18 The aim of this study was
to derive a simple score for estimating the
long-term risk of osteoporotic and hip frac-
ture in patients with MS.
METHODS Data source. Information for this study was
obtained from the General Practice Research Database (GPRD).
The GPRD comprises prospectively collected computerized
medical records for more than 10 million patients under the care
of general practitioners in the United Kingdom. It has been the
source for numerous epidemiologic studies, and the accuracy
and completeness of these data have been well-validated and
documented.19 Previous studies of GPRD data have shown a
high level of data validity with respect to the reporting of frac-
ture.20 GPRD data have been linked to the national Hospital
Episode Statistics in England for approximately 45% of all prac-
tices.21 In this study, data were linked from April 1997 until
March 2008.
Study population. The study population has been described
previously and is available under an open access license.2 In
short, we identified all patients aged 18 years or older with at
least one recorded diagnosis of MS during the period of GPRD
(January 1987–August 2009) or Hospital Episode Statistics data
collection (April 1997–March 2008). Patients with a history of
MS before the start of valid data collection were excluded. Each
patient with MS was matched by year of birth, sex, and practice
to 6 control subjects. The index date of MS diagnosis was the
date of the first record of MS, after start of valid data collection.
Control patients were assigned the same index date as their
matched case patient. Each patient was followed from index date
to the end of data collection, the date of transfer of the patient
out of the practice area, or the patient’s death, whichever came
first. For the development of the prediction model, we followed
FRAX in the decision to exclude patients who were currently
treated with osteoporosis medication or who had previously
taken medicines against osteoporosis. Therefore, we excluded all
patients who had ever used osteoporosis treatment at baseline,
which included prescriptions of bisphosphonates, raloxifene,
strontium ranelate, and parathyroid hormone.
Study outcomes. All patients were followed up for the occur-
rence of fractures. The types of fracture were classified according
to the International Classification of Diseases (ICD-10) catego-
ries. These included skull (S02), neck (S12), ribs (S22), pelvis
(S32), shoulder (S42), forearm (S52), hand (S62), hip/femur
(S72), ankle (S82), foot (S92), or unspecified fractures (T02,
T08, T10, and T12). A clinical osteoporotic fracture was defined
as a fracture of the radius/ulna, vertebrae, femur, hip, humerus,
pelvis, or ribs.
Risk factors. The presence of risk factors was assessed by re-
viewing the computerized medical records at baseline. Potential
risk factors included older age, female sex, low BMI, being a
smoker, drinking alcohol, history of falling 3 months–1 year
before, history of fracture, and history of chronic diseases
(congestive heart failure, rheumatoid arthritis, cerebrovascu-
lar disease, inflammatory bowel disease, dementia, depres-
sion, epilepsy, and chronic obstructive pulmonary disease). In
addition, evidence of fatigue, visual disturbances, vertigo, dizzi-
ness, imbalance, disturbance of sensation, spasticity, sexual dys-
function, paroxysmal symptoms, cognitive dysfunction, vitamin
D deficiency, and proxy indicators of increased disability (home
visits by the general practitioner, nursing care, patient receiving
residential care/living in a care home, or patient using a wheel-
chair or walking aid) 6 months before the index date were con-
sidered. Further, prescriptions for PO or IV administered GCs,
statins, antiarrhythmics, antidiabetics, antidepressants, antipsy-
chotics, hypnotics/anxiolytics, asthma medication, anticonvul-
sants, hormone replacement therapy, vitamin D, levothyroxine,
baclofen, opioids (potencies equivalent to tramadol or higher),
nonsteroidal anti-inflammatory drugs, meprobamate, tizanidine,
dantrolene, modafinil, methylphenidate, or amantadine 6
months before the index date were also considered potential risk
factors.
Statistical analysis. Cox proportional hazards models were
used to calculate the long-term risk of osteoporotic and hip frac-
ture. The Cox model allows calculation of an individual’s proba-
bility of fracture (i.e., survivor function) for each set of patient
characteristics. For the analysis of long-term risk, we first fitted
the regression model with all possible risk factors, which were
determined at baseline. All characteristics, except age, were in-
cluded as categorical variables in the regression models. For
Neurology 79 August 28, 2012 923
BMI, we used categories "20 kg/m2, 20–25 kg/m2 (reference),
#25 kg/m2, and unknown. Smoking status was divided over
current smoking, ex-smoking, never smoking (reference), and
unknown smoking status. Alcohol consumption was similarly
categorized as current, ex, never (reference), and unknown. All
other variables addressing medical history and the prescription of
drugs were separately added and were categorized as yes or no.
We used the PHREG procedure in SAS with forward selection
and a significance level of 0.05. This resulted in a list of variables
that were possible candidates for our prediction model.
For osteoporotic fracture, the following variables came out of
the forward selection. MS, sex, age, use of GCs in the prior 6
months, use of anticonvulsants in the prior 6 months, history of
fracture, current smoking, and BMI #25 kg/m2. Because of
clinical importance, we decided to add BMI "20 kg/m2, use
of antidepressants in the prior 6 months, and history of falling 3
months–1 year before. For the prediction of hip fracture, for-
ward selection resulted in the variables MS, age, use of antidia-
betics, baclofen, and amantadine in the prior 6 months, history
of fatigue in the prior 6 months, BMI"20 kg/m2 and BMI#25
kg/m2. In this case, we considered sex, use of GCs in the prior 6
months, use of antidepressants in the prior 6 months, history of
falling 3 months–1 year before, history of fracture, and current
smoking important variables to add. However, because there
were only 104 hip fractures among the patients with MS and con-
trol subjects, we were restricted to 10 predictors. Therefore, we
dropped the use of antidiabetics, baclofen, and amantadine in the
prior 6 months. We also dropped a history of fracture, because this
variable led to ! of 0. Next, we investigated possible statistical inter-
actions of these selected variables with MS. To account for multiple
comparisons, we applied a Bonferroni correction. None of the inter-
action terms was subsequently added to the model.
The ! coefficients in the final Cox model were converted
into integer risk scores. The value of each integer was calculated
as the rounded sum of the Cox model predictor scores, multi-
plied by 10. The 5- and 10-year risks of fracture were then esti-
mated using these scores, conditional on patient survival.
Various methods were used to test the fitting of the Cox models,
including a test of the proportional hazards assumption. We also
compared the observed 5-year probability of fracture (based on
the Kaplan-Meier estimate) with the probability predicted by the
Cox model. To assess the internal validity of the model further,
the C-statistic was calculated, and we performed a 10-fold cross-
validation. We applied the shrinkage factor that we found to the
! coefficients of the model, and we adjusted the C-statistic for
overestimation. We compared 10-year risks of osteoporotic and
hip fracture as predicted by FRAX and by the present risk score.
As a sensitivity analysis, we also evaluated backward selection
and stepwise selection instead of forward selection. Both meth-
ods resulted in exactly the same set of predictors, both for osteo-
porotic and for hip fracture. All data management and statistical
analyses were conducted using SAS 9.1/9.2 software.
Standard protocol approvals, registrations, and patient
consents. The study was approved by the Independent Scien-
tific Advisory Committee of the GPRD.
RESULTS The study population consisted of 5,494
patients with MS and 32,669 population-based con-
trol subjects.
Of all patients with MS, 70% were female and the
mean age at the index date (first recorded diagnosis
of MS) was 44.5 years. The median duration of
follow-up after the index date was 4.5 years. There
were more current smokers among patients with MS
than among control subjects, and there were more
patients with MS with BMI"20 kg/m2. Six months
before the index date, patients with MS had used
significantly more antidepressants (17.7%), anticon-
vulsants (6.6%), and GCs (5.7%) than the control
subjects (8.3%, 1.2%, and 1.4%, respectively). Fur-
ther descriptive details of the study participants are
shown in table 1. Among all patients with MS, 163
experienced an osteoporotic fracture during follow-
up, and 36 patients sustained a hip fracture. In the
control group, there were 668 osteoporotic fractures
and 68 hip fractures. The most common osteopo-
rotic fractures were fractures of the radius/ulna: there
were 61 patients with MS with these types of frac-
tures and 298 control subjects.
Table 2 presents the risk score for osteoporotic
and hip fracture in relation to various patient charac-
teristics. The overall score for a patient is the cumu-
lative score of the various risk factors. For example, a
woman with MS aged 60 years, with a history of
fracture and antidepressant use in the previous 6
months, had a risk score for osteoporotic fracture of
42 ($4 points for having MS, $3 points for being
female,$30 points for her age,$4 points for history
of fracture, and $1 point for the use of antidepres-
sants). The figure displays the 5- and 10-year risks of
fracture (percentages) in relation to the risk score.
The corresponding 5-year risk of osteoporotic frac-
ture for the patient described is 7.2%. To provide
some risk level landmarks: the predicted 5-year risk
of osteoporotic fracture for a 70-year-old woman
without any other risk factors was 4.9% (score !
38). If the woman also had a history of fracture, her
risk changed to 7.2% (score ! 42). A female patient
with MS of the same age and with a history of frac-
ture had a 5-year risk of 10.5% (score ! 46). The
C-statistic was moderate (0.67) for the prediction of
osteoporotic fracture and excellent (0.89) for the pre-
diction of hip fracture.
Table 3 shows that FRAX underestimated risks of
fracture for patients with MS, especially risks of hip
fracture.
DISCUSSION In this study, we developed a simple
score for estimating the long-term risk of osteopo-
rotic and hip fracture in patients with MS. In com-
parison with the FRAX calculator,13 our risk score
contains several new risk factors that have been
linked with fracture. These include MS, the use of
antidepressants, the use of anticonvulsants, history
of falling, and history of fatigue. The score was
developed in a cohort of patients with MS and
population-based control subjects, and the presence
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of MS proved to be a useful characteristic in the pre-
diction of osteoporotic and hip fracture.
There are various explanations for the association
between MS and fracture, which include fall- and
bone-related mechanisms. Previous studies have
shown that patients with MS have an increased
risk of osteoporosis,4–9 which may result from im-
mobilization,6,7 vitamin D deficiency,6,9 exposure
to GCs,4,7,22 and the inflammatory nature of the dis-
ease.23 The decrease in bone formation with immo-
bility is probably caused by the reduction of
mechanical stress, which results in disruption of the
osteocyte network.24 GC-induced osteoporosis can
be explained by apoptosis in osteoblasts and osteo-
cytes or suppression of their differentiation.25 In the
present study, we investigated the predictive value of
GC use as a risk factor for osteoporotic and hip frac-
ture, and the recent use of GCs was indeed incorpo-
rated in our models. Further, it has been recognized
that patients with MS are at increased risk of fall-
ing,10–12 which may be explained by poorer postural
balance, impaired vision, disability, or spasticity. Al-
though we had information on the occurrence of
falls, and history of falling was indeed selected as a
risk factor in our models, there may have been an
underrecording of falling in our study. The true con-
tribution of falling may therefore be greater than rep-
resented in our risk scores. However, because we
additionally incorporated MS as a risk factor, this
probably has captured risk of falling in an indirect
way. Recent use of GCs may also be a proxy for risk
of falling, because treatment with GCs may be initi-
ated because of a worsening of neurologic problems.
Table 1 Baseline characteristics of patients
with MS and control subjects
Characteristic
Patients
with MS
(n! 5,494)
Control
subjects
(n! 32,669)
Female sex, n (%) 3,833 (69.8) 22,738 (69.6)
Age at index date
Mean 44.5 44.3
By category, n (%)
18–29 y 670 (12.2) 4,016 (12.3)
30–39 y 1,443 (26.3) 8,649 (26.5)
40–49 y 1,614 (29.4) 9,661 (29.6)
50–59 y 1,044 (19.0) 6,184 (18.9)
60" y 723 (13.2) 4,159 (12.7)
Duration of follow-up, y,
median (range)
4.5 (0–20.6) 5.0 (0–20.6)
Smoking, n (%)
Never 2,114 (38.5) 14,805 (45.3)a
Current 1,521 (27.7) 7,062 (21.6)a
Ex 790 (14.4) 4,134 (12.7)a
Unknown 1,069 (19.5) 6,668 (20.4)
BMI, n (%)
<20 kg/m2 443 (7.9) 1,919 (5.9)a
20–25 kg/m2 1,904 (34.7) 11,146 (34.1)
25–30 kg/m2 1,295 (23.6) 8,591 (26.3)a
>30 kg/m2 878 (16.0) 5,347 (16.4)
Unknown 984 (17.9) 5,666 (17.3)
History of comorbidity, n (%)
Fracture 801 (14.6) 4,354 (13.3)a
Falling 343 (6.2) 928 (2.8)a
Fatigue 425 (7.7) 1,682 (5.1)a
Asthma 568 (10.3) 3,378 (10.3)
COPD 53 (1.0) 281 (0.9)
Congestive heart failure 31 (0.6) 146 (0.4)
Diabetes mellitus 151 (2.7) 804 (2.5)
Rheumatoid arthritis 28 (0.5) 207 (0.6)
Cerebrovascular incident 147 (2.7) 361 (1.1)a
Epilepsy 129 (2.3) 435 (1.3)a
History of drug use 6mo
before, n (%)
Statins 220 (4.0) 977 (3.0)a
Antidepressants 974 (17.7) 2,709 (8.3)a
Antipsychotics 72 (1.3) 294 (0.9)a
Anxiolytics/hypnotics 456 (8.3) 1,290 (3.9)a
Anticonvulsants 364 (6.6) 408 (1.2)a
Opioids 156 (2.8) 320 (1.0)a
PO/IV glucocorticoids 311 (5.7) 445 (1.4)a
Vitamin D 35 (0.6) 128 (0.4)a
Abbreviations: BMI! bodymass index; COPD! chronic ob-
structive pulmonary disease; MS!multiple sclerosis.
a Statistically significant difference (p" 0.05) between pa-
tients with MS and control subjects, based on "2 test.
Table 2 Risk score of fracture
Characteristic
Score
osteoporotic
fracture
Score
hip
fracture
Patient with MS 4 13
Female sex 3 2
Age (for every 10 y) 5 11
Use of PO/IV glucocorticoids
in the prior 6mo
1 3
Use of antidepressants in the
prior 6mo
1 3
Use of anticonvulsants in the
prior 6mo
6
History of falling 3mo–1 y
before
4 6
History of fracture ever before 4
History of fatigue in the prior
6mo
18
Current smoker 2 4
BMI<20 kg/m2 2 7
BMI>25 kg/m2 %1 %6
Abbreviations:BMI!bodymass index;MS!multiplesclerosis.
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In addition to the presence of MS, the recent use
of antidepressants and anticonvulsants were also cov-
ered in our risk score. One of the possible mecha-
nisms by which antidepressant use may contribute to
fracture risk is through an increased risk of falling.26
Moreover, the microarchitecture of bone may be al-
tered,27 and depression itself might also increase risk
of fracture.28 The mechanisms by which anticonvul-
sants weaken the skeleton are not fully understood.
One theory is that they accelerate vitamin D hy-
droxylation to polar inactive metabolites, resulting in
hypocalcemia, secondary hyperparathyroidism, in-
creased bone turnover, and higher rates of bone
loss.29
We tested the accuracy of our models in various
ways. In terms of the ability to discriminate between
patients who did and who did not sustain a fracture,
both models performed reasonably well with a
C-statistic of 0.67 for the prediction of osteoporotic
fracture and 0.89 for the prediction of hip fracture.
In addition, we investigated the concordance be-
tween predicted and actual probabilities, i.e., the cal-
ibration of the model. This was done by a 10-fold
cross-validation; the shrinkage factors were close to
1. Overall, the predictive accuracy of our models was
good, as tested by internal validation.
Our study has many advantages. As far as we
know, we are the first to provide a clinical risk score
for fracture risk estimation involving MS as a risk
factor. Our data are representative of the total UK
population, and we had detailed longitudinal infor-
mation on drug prescribing and other risk factors for
fracture, such as history of falling, low BMI, and
smoking status.
There are some limitations, however. The pre-
dicted long-term risks of fracture vary between 0 and
1. This raises the issue of selecting an optimal cutoff
point to determine which patients would, for exam-
ple, be candidates for BMD screening or pharmaco-
logic treatment. This cutoff value depends on a
complex benefit-risk assessment and on individual
perception of risk and was not investigated in the
present study. The first symptoms of MS can arise
several years before MS is diagnosed, and, therefore,
the date of diagnosis as recorded on the GPRD is not
entirely reliable. We did not have routinely collected
information on the degree of disability in patients
with MS. Vitamin D levels were not routinely col-
Figure Risk (percentage) of osteoporotic or hip fracture in relation to risk score
CI! confidence interval.
Table 3 Ten-year probability of fracture as
predicted by FRAX and the present
risk score by sex and age
Osteoporotic
fracture Hip fracture
FRAXa
Present
risk
scoreb FRAXa
Present
risk
scoreb
Men
40 2.5 2.4 0.1 0.2
50 2.7 3.9 0.2 0.7
60 3.9 6.1 0.6 2.2
70 5.6 9.6 1.6 6.5
80 7.2 14.8 3.9 18.6
Women
40 2.6 3.3 0.2 0.3
50 3.5 5.2 0.3 0.9
60 6.1 8.2 1.0 2.8
70 11.0 12.9 3.1 8.2
80 18.0 19.6 8.6 22.8
a Using http://www.shef.ac.uk/FRAX16 for the UK (accessed
5 March 2012), incorporating age, sex, and a body mass
index of 22.5 kg/m2.
b Incorporating age, sex, and multiple sclerosis as risk
factors.
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lected. Moreover, GPRD does not routinely collect
BMD measurements, and we had no information on
parental history of fracture (which is included in
FRAX as a risk factor). The number of vertebral and
rib fractures recorded in this study is probably under-
reported. The true risks of osteoporotic fracture may
therefore be greater than reported in our study. The
risk score that we developed is preliminary in the
sense that it should be validated in an external popu-
lation.30 Another limitation is that the predicted risks
are based on a single measurement of risk factors,
with the underlying assumption that risk factors do
not change over time. Obviously, this assumption is
not true for many risk factors. Because of a relatively
low number of osteoporotic and hip fractures among
patients with MS, we built our model with data from
patients with MS and their control subjects. A score
that would be based on data from only patients with
MS would be a valuable addition to this field, but a
larger group of patients would then be needed. From
all 5,494 patients with MS, there were 1,011 patients
with more than 10 years of follow-up. Therefore, the
predicted 10-year fracture risks are based on a subset
of our cohort.
Overall, this is the first clinical risk score for frac-
ture risk estimation involving MS as a risk factor.
Our score may be a starting point for the communi-
cation of an individual’s fracture risk in patients
with MS.
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The Academy’s Neurology Career Center is working to bring experienced members together with
members who seek guidance on their career path. AAN Mentor Connect needs volunteer Mentors
who are willing to share their expertise, insights, and experiences with Mentees.
This flexible program, available only to AAN members, matches prospective Mentors and Mentees,
and enables you to develop a plan with the Mentee that has a mutually agreeable schedule and
expectations.
Enjoy the personal satisfaction of making a valued contribution to the career of a fellow AAN
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Editor’s Note to Authors and Readers: Levels of Evidence in Neurology®
Effective January 15, 2009, authors submitting Articles or Clinical/Scientific Notes to Neurology®
that report on clinical therapeutic studies must state the study type, the primary research ques-
tion(s), and the classification of level of evidence assigned to each question based on the AAN
classification scheme requirements. While the authors will initially assign a level of evidence, the
final level will be adjudicated by an independent team prior to publication. Ultimately, these levels
can be translated into classes of recommendations for clinical care. For more information, please
access the articles and the editorial on the use of classification of levels of evidence published in
Neurology.1-3
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